This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cosentyx
  • /
  • Efficacy at 24 Weeks and Long Term Safety, Tolerab...
Clinical trial

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Read time: 1 mins
Last updated:1st Sep 2011
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest